BTB06584

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

BTB06584 是一种新型乙酰羟酸合酶 (AHAS) 抑制剂，是一种有前景的抗结核分枝杆菌 (MTB) 药物靶点。

BTB06584 is a novel acetohydroxyacid synthase(AHAS) inhibitor, a promising drug target against Mycobacterium tuberculosis (MTB). BTB06584 is an IF1-dependent, selective inhibitor of the mitochondrial F1 Fo-ATPase.

In HL-1 cells, BTB06584 (100 μM) inhibits F1Fo-ATPase activity with no effect on the mitochondrial membrane potential (ΔΨm ) or O2 consumption. BTB06584 (100 μM) pretreatmet protects against ischaemic cell death in HL-1 cells prior to a period of ischaemia. ATP consumption is decreased following inhibition of respiration, and ischaemic cell death is reduced. BTB06584 efficiency is increased by IF1 overexpression and reduced by silencing the protein.

BTB06584 (1 μM; 24 hours) treatment rescued defective haemoglobin synthesis in zebrafish pinotage (pnt) mutants in which expression of the Atpif1a gene is lost. The concentrations of BTB06584 that restore haemoglobin biosynthesis also alter mitochondrial bioenergetics in living fish.

BTB

Endocrinology/Hormones

ATPase

ATPase| Acetohydroxyacid synthase

Metabolic Disease

——

219793-45-0

417.82

C19H12ClNO6S

>98% (HPLC)

DMSO: 84 mg/mL (201.04 mM)

O=S(C1=CC(OC(C2=CC=C(Cl)C=C2)=O)=C([N+]([O-])=O)C=C1)(C3=CC=CC=C3)=O

2-nitro-5-(phenylsulfonyl)phenyl 4-chlorobenzoate

(-20℃)

With Ice Pack

≥ 2 years